Ontology highlight
ABSTRACT:
SUBMITTER: Hehlmann R
PROVIDER: S-EPMC5668495 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
Hehlmann R R Lauseker M M Saußele S S Pfirrmann M M Krause S S Kolb H J HJ Neubauer A A Hossfeld D K DK Nerl C C Gratwohl A A Baerlocher G M GM Heim D D Brümmendorf T H TH Fabarius A A Haferlach C C Schlegelberger B B Müller M C MC Jeromin S S Proetel U U Kohlbrenner K K Voskanyan A A Rinaldetti S S Seifarth W W Spieß B B Balleisen L L Goebeler M C MC Hänel M M Ho A A Dengler J J Falge C C Kanz L L Kremers S S Burchert A A Kneba M M Stegelmann F F Köhne C A CA Lindemann H W HW Waller C F CF Pfreundschuh M M Spiekermann K K Berdel W E WE Müller L L Edinger M M Mayer J J Beelen D W DW Bentz M M Link H H Hertenstein B B Fuchs R R Wernli M M Schlegel F F Schlag R R de Wit M M Trümper L L Hebart H H Hahn M M Thomalla J J Scheid C C Schafhausen P P Verbeek W W Eckart M J MJ Gassmann W W Pezzutto A A Schenk M M Brossart P P Geer T T Bildat S S Schäfer E E Hochhaus A A Hasford J J
Leukemia 20170814 11
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-y ...[more]